Photo by: Epogen.com 10. Epogen- 2010 US Sales: $3.3 billion Company: Amgen Epogen is used to treat patients with a lower-than-normal number of red blood cells (anemia) caused by chronic kidney failure. Epogen stimulates the bone marrow to make more red blood cells and lessens the need for red blood cell transfusion. Amgen has an exclusive license to manufacture and market Epogen in the U.S. under an agreement with K.A., Kirin-Amgen, Inc. The drug first entered the U.S. market in 1989. Epogen falls under the category of biologic drugs, created by a biological process rather than a chemical one. At this point there are no legal regulatory provisions for generic versions of these drugs, which are deemed more complicated. However, one wildcard is the possibility of the introduction of the Quality Improvement Programâ€"a bundled payment system in dialysisâ€"which, if approved by the Centers for Medicare & Medicaid Services, will decrease dose utilization, and therefore the sales of Epogen beginning in 2012.
By Jill Weinberger, CNBC.com The pharmaceutical business is an extremely profitable one. According to the IMS Institute for Healthcare Informatics, spending on medicine in the U.S. alone exceeded $307 billion in 2010. For many drug makers, one money-spinner can carry a company for years, even longer
Jason Fitz and Frank Schwab join forces to recap the draft in the best way they know how: letter grades! Fitz and Frank discuss all 32 teams division by division as they give a snapshot of how fans should be feeling heading into the 2024 season. The duo have key debates on the Dallas Cowboys, New York Giants, New Orleans Saints, Los Angeles Rams, New England Patriots, Las Vegas Raiders and more.